{"filings":[{"id":1534838,"accession_number":"0001193125-26-298979","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-07-09T10:00:22+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics amends loan facility with Oxford Finance, extends Term A draw period to Dec 31, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment extends availability of remaining $15M Term A loans through Dec 31, 2026; upfront fee of $187,500.","If full $15M not drawn by Dec 31, 2026, non-utilization fee of 1% of undrawn amount applies.","If full $15M drawn, Term B loan availability extended to Sep 30, 2027; Term C loans restructured into two $20M tranches with revenue/clinical milestones.","Minimum revenue covenants begin Q2 2027 or later depending on capital raises; original facility up to $150M with $25M drawn in Nov 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":806798,"accession_number":"0001193125-26-253604","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-06-02T20:30:16+00:00","items":["5.07","9.01"],"status":"ready","headline":"Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["73% of outstanding shares (43.99M of 60.53M) represented at May 27, 2026 annual meeting, forming quorum.","Ian Clark elected as Class II director: 31,505,902 for, 3,255,231 withheld, 9,225,874 broker non-votes.","Christi Shaw elected as Class II director: 34,528,865 for, 232,268 withheld, 9,225,874 broker non-votes.","BDO USA ratified as independent auditor for FY 2026: 43,830,300 for, 80,223 against, 76,484 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482522,"accession_number":"0001193125-26-227920","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-05-18T12:00:16+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Greg Martini named CFO effective May 18, 2026; previously CFO of Ironwood Pharmaceuticals.","Marc Grasso steps down as CFO, stays as strategic advisor through Aug 1, 2026 for transition.","Compensation: $525K salary, 40% bonus target, $300K sign-on bonus, 325K stock option (4-year vest).","Company advancing miv-cel (KYV-101) toward potential first approval in stiff person syndrome.","Option grant of 325K shares as inducement under Nasdaq Rule 5635(c)(4); exercise price May 18 close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40250,"accession_number":"0001193125-26-219377","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-05-12T20:05:31+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.","Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.","Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.","Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.","Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97102,"accession_number":"0001193125-26-202610","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics appoints Nadia Dac as CCO; leads commercial launch for miv-cel in stiff person syndrome","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nadia Dac appointed Chief Commercial Officer effective May 4, 2026; has 30+ years experience in neurology and rare disease launches.","She will lead commercial strategy for miv-cel (KYV-101), which is poised for first approval in stiff person syndrome with neuroimmunology expansion.","Previously CCO at Omeros (launched Yartemlea) and Alder (launched Vyepti); held leadership roles at AbbVie, Novartis, Biogen.","Received inducement option for 300,000 shares vesting over 4 years (25% after 1 year, monthly thereafter); exercise at May 4 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97101,"accession_number":"0001193125-26-168287","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.","KYSA-8 registrational trial of miv-cel in stiff person syndrome achieved positive primary analysis results.","Conference call held April 22, 2026 to review both data sets; slides furnished as Exhibit 99.1.","Data presented at AAN 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97100,"accession_number":"0001193125-26-167512","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.","81% of patients achieved ≥20% improvement in T25FW; 67% of walking-aid users no longer needed assistance.","All 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.","Company plans to submit BLA for miv-cel in SPS; data also support potential in myasthenia gravis.","Natural history study of 153 SPS patients showed minimal improvement with current treatments, underscoring unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97099,"accession_number":"0001193125-26-162755","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.","57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up; responses deepened over time.","100% were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn/complement inhibitors through Week 24.","No high-grade CRS or ICANS; two transient grade 3/4 neutropenia events resolved; safety supports outpatient administration.","Median follow-up 10.2 months (range 3.3–16.0); company enrolling Phase 3 registrational trial across 14 sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111604,"accession_number":"0001193125-26-126216","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.","Cash and equivalents $279.3M; raised $147.5M in equity and $25M from loan facility.","SPS registrational trial met primary endpoints; BLA submission expected 1H 2026; launch-ready by YE 2026.","Phase 3 gMG trial enrolling; first patient Dec 2025; 14 sites active across three geographies.","Positive PMS Phase 1 data: 83% (5/6) patients achieved EDSS improvement; no high-grade CRS/ICANS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111603,"accession_number":"0001193125-26-065320","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna appoints Andrew Miller and Sravan Emany to Board; Spiegelman resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Miller (Karuna founder) appointed Class III director; granted option valued at $262k and RSUs valued at $87.5k.","Sravan Emany (Beam CFO) appointed Class I director and Audit Committee Chair; receives same initial equity awards.","Daniel Spiegelman resigned Feb 24, no disagreement with company operations, policies or practices.","Miller brings drug development experience from Karuna's $14B BMS acquisition; Emany adds capital markets and rare disease expertise.","Both directors receive cash comp: $40k board retainer plus committee fees; equity vests over 3 years with full acceleration on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111602,"accession_number":"0001193125-26-034464","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.","Outgoing CTO Karen Walker retires; will consult on BLA submission for miv-cel in stiff person syndrome.","Pujols receives an inducement option for 300,000 shares vesting over 4 years under the 2024 Inducement Plan.","The inducement plan was amended to increase authorized shares by 1,000,000 to 5,000,000 total.","Kyverna advances toward potential commercial launch of miv-cel for autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111601,"accession_number":"0001193125-26-009810","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Kyverna plans BLA for miv-cel in SPS in 1H 2026; Christi Shaw appointed Executive Chair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BLA submission for miv-cel in stiff person syndrome expected in 1H 2026 following positive registrational data.","Cash, cash equivalents, and marketable securities approx. $279M as of Dec 31, 2025; follow-on offering raised ~$105M.","First patient enrolled in Phase 3 registrational trial of miv-cel in generalized myasthenia gravis.","Christi Shaw (former Kite CEO) appointed Executive Chairperson; Ian Clark remains on board.","Company plans to achieve SPS launch readiness by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128245,"accession_number":"0001213900-25-123033","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kyverna prices $100M public offering of 13.3M shares at $7.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 13,333,333 shares of common stock at $7.50/share; gross proceeds ~$100M.","Underwriters granted a 30-day option to purchase up to 1,999,999 additional shares at $7.50/share less discounts.","Net proceeds for general corporate purposes, including R&D, capex, working capital.","Expected closing on or about December 18, 2025; directors, officers, affiliates subject to lock-up through January 31, 2026.","Joint book-running managers: J.P. Morgan, Leerink Partners, Morgan Stanley, Wells Fargo Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128244,"accession_number":"0001193125-25-318469","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).","Trial KYSA-8 evaluates fully human autologous CD19 CAR T-cell therapy with CD28 co-stimulation.","Company to host conference call on Dec 15, 2025 at 8:00 AM ET to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128243,"accession_number":"0001193125-25-318377","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna reports positive Phase 2 topline data for miv-cel in stiff person syndrome; BLA planned 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 46% median improvement in timed 25-foot walk at Week 16 (p=0.0002).","81% of patients exceeded 20% improvement in T25FW; 67% no longer needed walking aid (12 patients).","All secondary endpoints statistically significant (p<0.0001); 100% free of immunotherapies post-dose.","No high-grade CRS or ICANS; manageable Grade 3/4 neutropenia observed in some patients.","Company plans to submit BLA to FDA for SPS in first half of 2026; RMAT and Orphan Drug designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128242,"accession_number":"0001193125-25-277569","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna Therapeutics reports Q3 results, positive gMG interim data, $150M loan facility, SPS data early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Kyverna reported Q3 2025 net loss of $36.8M ($0.85 per share), R&D expenses $30.5M, G&A $8.3M; cash $171.1M as of Sep 30, 2025.","Positive interim Phase 2 data in generalized myasthenia gravis: all primary and secondary endpoints met, 100% of patients achieved sustained reductions in MG-ADL and QMG at 24 weeks.","Topline data from registrational stiff person syndrome trial expected early 2026 (narrowed from 1H 2026); BLA submission anticipated in 1H 2026.","Closed up to $150M loan facility with Oxford Finance, initial $25M drawn; cash runway extended into 2027.","On track to file IND for KYV-102 (whole blood rapid manufacturing) in Q4 2025; Phase 3 gMG enrollment by year-end."],"consensus_eps_estimate":-0.9911,"consensus_eps_actual":-2.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128241,"accession_number":"0001193125-25-261719","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Kyverna secures up to $150M debt facility from Oxford Finance; SPS data readout accelerated","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Non-dilutive term loan facility of up to $150M; initial draw of $25M on Nov 3, 2025.","Loan matures Oct 1, 2030; floating interest at 1M SOFR + 5.00% (floor 3.75%); interest-only to Nov 2028/2029.","Cash runway extended into 2027, supporting SPS BLA filing and MG Phase 3 trial.","Topline registrational Phase 2 SPS data now expected early 2026 (narrowed from 1H 2026); BLA filing 1H 2026.","MG Phase 3 enrollment to start by year-end 2025; updated Phase 2/3 data expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128240,"accession_number":"0001193125-25-254698","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.","Conference call held same day at 8 a.m. Eastern Time to discuss results; slides furnished as Exhibit 99.1.","No specific efficacy or safety figures included in the filing text; detailed data in attached slide deck.","Kyverna is a clinical-stage biotech focused on CAR T-cell therapies for autoimmune diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128239,"accession_number":"0001193125-25-254571","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna reports positive Phase 2 interim data for KYV-101 in gMG; 100% response rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% (6/6) of patients achieved clinically meaningful reductions in MG-ADL and QMG at 24 weeks.","Mean reductions of -8.0 points (MG-ADL) and -7.7 points (QMG) from baseline; responses seen as early as 2 weeks.","No high-grade CRS or ICANS observed; one SAE of Grade 4 neutropenia resolved to Grade 1.","All patients free of nonsteroidal immunosuppressants, high-dose steroids, FcRn, and complement inhibitors.","Company plans to initiate Phase 3 portion of KYSA-6 trial by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145031,"accession_number":"0001193125-25-217434","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Steve Liapis resigns from Kyverna board effective Sept 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Liapis, Ph.D. notified the board of his resignation effective September 30, 2025.","Resignation is not due to any disagreement with the company's operations, policies, or practices.","Board size will be reduced from eight to seven directors upon resignation.","Christi Shaw, a current board member, appointed to the Audit Committee to fill the vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145030,"accession_number":"0000950170-25-107300","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna Q2 net loss $42.1M, cash $211.7M; advances KYV-101 in SPS and MG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $42.1M ($0.97/share) vs $28.8M in Q2 2024; R&D expenses rose to $35.8M from $27.3M.","Cash and equivalents $211.7M as of June 30, 2025, funding operations into 2027.","Phase 2 SPS registrational trial enrollment complete; topline data and BLA filing expected 1H 2026.","Phase 3 MG trial (~60 patients) enrollment to start by year-end 2025; interim Phase 2 data in Q4 2025.","Marc Grasso appointed CFO in June 2025; KYV-102 IND filing expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163412,"accession_number":"0001213900-25-059289","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics appoints Marc Grasso as CFO; Ryan Jones moves to advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marc Grasso appointed CFO effective June 30, 2025; previously CFO of Alector (ALEC) and Kura Oncology (KURA).","Outgoing CFO Ryan Jones will serve as strategic advisor through August 8, 2025; receives severance including 9 months salary and continued vesting.","Grasso receives base salary of $510,000, sign-on bonus of $250,000, and option for 450,000 shares vesting over four years.","Grasso brings over 25 years of experience in public company finance and biotech investment banking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163411,"accession_number":"0000950170-25-080896","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Kyverna Therapeutics shareholders elect two Class I directors and ratify BDO as auditor at 2025 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["30,546,469 shares (70.67% of outstanding) represented at May 29, 2025 Annual Meeting.","Beth Seidenberg, M.D. elected with 18,161,970 votes for, 2,508,848 withheld.","Fred E. Cohen, M.D., D. Phil. elected with 18,513,181 votes for, 2,157,637 withheld.","Ratification of BDO USA, P.C. as auditor for 2025 passed with 30,374,716 for, 142,212 against, 29,541 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163410,"accession_number":"0000950170-25-070286","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna completes SPS Phase 2 enrollment; BLA filing now 1H 2026; Q1 net loss $44.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in KYSA-8 pivotal Phase 2 trial of KYV-101 in stiff person syndrome; topline data 1H 2026.","BLA filing for KYV-101 in SPS accelerated to 1H 2026 (from prior 2026 guidance).","FDA aligns on registrational Phase 3 for myasthenia gravis; interim Phase 2 data expected 2H 2025.","Cash and equivalents $242.6M; runway into 2027 supports first BLA, Phase 3 MG, and pre-launch activities.","Workforce reduced ~16% in Q1 2025; Q1 net loss $44.6M ($1.03/shr) vs $26.7M ($1.12/shr) in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181337,"accession_number":"0000950170-25-046176","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics enters into $50M at-the-market equity offering facility with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC allows sale of up to $50M of common stock from time to time.","Agent compensation set at 3.0% of gross sales price per share sold.","Company has no obligation to sell any shares under the Sales Agreement.","Sales will be made under Company's existing shelf registration statement (Form S-3) filed same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181336,"accession_number":"0000950170-25-046052","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna reports 2024 net loss $127.5M; cash runway into 2027; SPS trial 70% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $127.5M ($3.33 loss per share) for full year 2024 vs $60.4M loss in 2023.","Cash, equivalents and marketable securities $286.0M as of Dec 31, 2024; expected runway into 2027.","FDA aligned on registrational Phase 2 design for KYV-101 in stiff person syndrome; 70% enrolled, topline data 1H 2026.","Phase 2 interim data in myasthenia gravis and Phase 1 data in lupus nephritis expected in 2H 2025.","KYV-102 IND filing planned for 2H 2025; management team and board strengthened."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181335,"accession_number":"0000950170-25-007220","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kyverna appoints Naji Gehchan as Chief Medical and Development Officer; grants 425,000 option shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Naji Gehchan, MD/MBA, joins as Chief Medical and Development Officer; led clinical development at Eli Lilly including imlunestrant.","Inducement grant of options for 425,000 shares under 2024 Inducement Equity Plan; exercise price at Jan 22 closing price.","Options vest over 4 years (25% at 1-year anniversary, remainder monthly thereafter) contingent on continued service.","Dominic Borie, former President of R&D, transitions to Strategic Advisor to the CEO and Board.","Gehchan brings 20+ years experience in immunology and late-stage development for Kyverna's KYV-101 CAR-T program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181334,"accession_number":"0001213900-25-002831","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.","Cash runway into 2027 with $321.6M cash and securities as of Sep 30, 2024.","Myasthenia gravis: confirm registrational path 1H 2025, interim Phase 2 data 2H 2025.","Lupus nephritis: Phase 1 data expected 2H 2025; KYV-102 IND filing 2H 2025.","Company pivoting to late-stage development and commercialization with CD19 CAR T construct KYV-101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198147,"accession_number":"0000950170-24-131074","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kyverna CMO James Chung resigns; receives $220K severance and COBRA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO James Chung's employment terminated effective November 22, 2024.","Severance of $220,000 (6 months base salary) plus COBRA premiums for up to 6 months.","Stock options cease vesting as of Separation Date; release of claims signed.","No replacement named; Company expresses best wishes in future endeavors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198146,"accession_number":"0000950170-24-126342","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Kyverna Q3 net loss $34.3M; CMO James Chung resigns effective Nov 22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.3M ($0.80 per share) vs. $15.5M loss in prior-year quarter.","Cash, equivalents and marketable securities $321.6M as of Sep 30, 2024.","CMO James Chung, M.D., Ph.D. resigns effective Nov 22; search for replacement underway.","CEO Warner Biddle appointed; Board adds Christi Shaw and Mert Aktar.","KYV-101 advances: Phase 2 dosing in myasthenia gravis; RMAT and Orphan Drug designations in multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198145,"accession_number":"0001213900-24-089095","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics appoints cell therapy veteran Mert Aktar to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Mert Aktar as Class III director, effective Oct 20, 2024; joins Audit and Science & Technology Committees.","Aktar currently CEO of Receptive Bio; previously SVP Global Head of Corp Dev at Kite Pharma; over 20 years biopharma experience.","As non-employee director, receives $40k/yr cash, $10k Audit, $7.5k SciTech committee fees; plus $350k option grant vesting monthly over 3 years.","Appointment adds cell therapy and corporate development expertise as Kyverna advances KYV-101 in autoimmune disease trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214276,"accession_number":"0001213900-24-078736","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.","Biddle receives 2,579,259-share option (4-year vest, 1-yr cliff), $625K salary, $650K sign-on bonus, and up to $150K relocation.","Peter Maag, Ph.D. resigned as CEO and director Sept 13; will provide contractor services for up to 6 mo at $45,833/mo plus $550K severance.","Christi Shaw appointed Class II director; granted option for $350K in shares vesting over 36 months; succeeded Brian Kotzin, who resigned.","Company adopted 2024 Inducement Equity Incentive Plan reserving 4M shares for new-hire equity grants, used for Biddle's option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214275,"accession_number":"0000950170-24-095433","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.","Cash, equivalents & marketable securities $346.2M as of June 30, 2024.","No severe ICANS or CRS Grade ≥3 in 36 autoimmune patients treated with KYV-101.","100% manufacturing success for KYV-101 across 36 patients.","Received FDA RMAT designations for Stiff-Person Syndrome and Myasthenia Gravis."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214274,"accession_number":"0000950170-24-083570","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kyverna receives FDA RMAT designation for KYV-101 in refractory stiff-person syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for KYV-101, an autologous CD19 CAR T-cell therapy.","Designation based on positive clinical outcomes from named-patient use in Germany for refractory stiff-person syndrome (SPS).","RMAT enables accelerated development, senior FDA guidance, and use of surrogate endpoints for potential approval.","Kyverna plans to initiate KYSA-8 trial; quote from investigator: 'could drastically change treatment landscape for SPS.'","CEO Peter Maag highlighted potential for durable, immunosuppressant-free remission in SPS patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233516,"accession_number":"0000950170-24-073312","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.","KYV-101 data covered experience across multiple autoimmune diseases and sites, presented by James Chung, MD, PhD of Kyverna.","Panel discussion featured academic and Kyverna experts on KYV-101's potential in rheumatologic autoimmune indications.","No specific numerical efficacy or safety results were disclosed in the furnished presentation materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233515,"accession_number":"0000950170-24-059613","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna Q1 net loss $26.7M; cash $369.8M; treated 30 patients cumulatively","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.7M ($1.12 per share) vs net loss of $11.1M ($12.10 per share) in Q1 2023.","Cash, cash equivalents and marketable securities $369.8M as of March 31, 2024, including $336.2M net IPO proceeds.","Treated 30 patients cumulatively with KYV-101: 8 myasthenia gravis, 7 lupus nephritis, 4 multiple sclerosis.","KYV-101 granted FDA Orphan Drug Designation for myasthenia gravis; upcoming data at EULAR, ECTRIMS, ACR.","Net cash used in operations $25.5M in Q1 2024 vs $11.5M in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251596,"accession_number":"0000950170-24-036410","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyverna reports FY 2023 net loss of $60.4M; IPO raised $366.9M in Feb 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.4M ($89.61/share) vs. $28.9M ($63.43/share) in FY 2022; cash burn $52.4M in operating activities.","Cash, equivalents and marketable securities $57.5M as of Dec 31, 2023; Feb 2024 IPO gross proceeds ~$366.9M.","Treated 14 autoimmune patients with KYV-101 CAR T therapy; FDA cleared Phase 2 trials in MS, MG and Phase 1/2 in systemic sclerosis.","Received FDA Fast Track Designations for KYV-101 in refractory MG, refractory progressive MS, and lupus nephritis.","Upcoming data releases at EULAR (Q2 2024), ECTRIMS (Q3 2024) and ACR (Q4 2024) for KYV-101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251595,"accession_number":"0001193125-24-032161","cik":1994702,"company_name":"Kyverna Therapeutics, Inc.","ticker":"KYTX","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Kyverna Therapeutics completes IPO of 16.7M shares at $22.00, gross proceeds $366.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $366.9M from IPO including full exercise of underwriter option to purchase 2.175M additional shares.","Shares listed on Nasdaq Global Select Market under ticker KYTX.","Amended charter and bylaws effective upon closing include classified board, exclusive forum provisions, and no cumulative voting.","Authorized capital: 490M shares of common stock and 10M shares of undesignated preferred stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":531350160.93830043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}